Abstract 811P
Background
Cervical cancer disproportionately affects patients (pts) in developing countries and is one of the leading causes of death in Latin America (LatAm). Understanding the epidemiological landscape of cervical cancer is warranted to plan prevention and treatment strategies for the continent.
Methods
The EVITA LATAM (LACOG 0820) study is a multicenter retrospective and prospective cohort of pts with cervical cancer FIGO Stage IB2 to IVA diagnosed after January 2018. Its primary objective is to describe the histologic subtypes and stages of cervical cancer in Latin America. We hereby describe demographic, clinical, and pathologic characteristics, and explore factors associated with diagnosis in earlier stages.
Results
From Nov/2021 to Jan/2023, 516 pts were included in 12 centers across Brazil, Argentina, Peru, and the Dominican Republic. Median age was 45.0 (range: 21.8 – 90.5) years, 213 (41.3%) were white and 244 (47.3%) were of mixed race. Current or former smoking was reported by 133 (25.7%) pts; 265 (51.3%) pts did not complete secondary education, and 441 (85.5%) were treated in public institutions. Four (0.8%) pts had received HPV vaccination and 73 (14.1%) never used contraception. PAP smear had never been performed by 62 (12.0%) patients and 126 (24.4%) received PAP smear regularly. Regarding histology, 420 (81.4%) pts presented with squamous cell carcinoma, and 66 (12.8%) with adenocarcinoma. Stages are described in the table. ECOG PS was 2 or worse in presentation for 58 (11.2%). Performing PAP smears regularly was associated with diagnosis at earlier stages (OR 1.69, 95%CI 1.15 - 2.49, P-value 0.0072).
Table: 811P
FIGO stages and screening program adherence
| Overall | Regular PAP smear | Not regular PAP smear | |
| N = 508 | N = 122 | N = 386 | |
| Stage (N, %)a | |||
| I | 32 (6.3%) | 12 (9.8%) | 20 (5.2%) |
| II | 170 (33.5%) | 48 (39.3%) | 122 (31.6%) |
| III | 247 (48.6%) | 52 (42.6%) | 195 (50.5%) |
| IV | 59 (11.6%) | 10 (8.20%) | 49 (12.7%) |
Ordinal regression, OR 1.69, 95%CI 1.15 - 2.49, P-value 0.0072.aEight patients did not have stage information so they were excluded from this table.
.Conclusions
This large study in LatAm findings showed that low rates of HPV vaccination and PAP smear coverage remain alarming, and less than half of pts received PAP smear regularly. More efficient HPV vaccination strategies synchronized with well-conducted Pap smear-based screening should be prioritized in LatAm countries.
Clinical trial identification
NCT04947605.
Editorial acknowledgement
Legal entity responsible for the study
Latin American Cooperative Oncology Group (LACOG).
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11